Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Microsoft (MSFT) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Microsoft — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Microsoft trades at $490.65 (market cap $3.74T). The key difference: Microsoft is far larger — about 126.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Microsoft pays a 0.72% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYMSFT
Market Cap
$29.60B$3.74T
Sector
HealthTechnology
52-Week High
$491.22$542.07
52-Week Low
$205.48$352.83
Enterprise Value
$27.56B$3.72T
Volume
36,654,621
Dividend Yield
0.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Microsoft

Microsoft (MSFT) trades at $493.21, down 2.54% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 estimate. Revenue grew to $281.72 billion in 2025, supported by a net income margin of 40.31% and robust cash flow from operations of $136.16 billion. Recent news highlights AI leadership and Azure momentum, though capital expenditure concerns persist.

Outlook remains positive with an 80.49% analyst buy rating and a $555 consensus price target, implying over 12% upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 28.07, and macroeconomic volatility. The stock's fundamentals and institutional support suggest long-term growth potential, but investors should monitor execution on AI investments and spending trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Microsoft

Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.

Read more on MSFT